Kornimate/medical-research-clean huggingface dataset:
examining the effects of a mobilization with movement and a dynamic stretch with over pressure on hip flexion.

Conditions: Hip; Anomaly

Summary: the purpose of this study is to compare the effects of a mobilization with movement (mwm) technique performed by a physical therapist with those of a dynamic stretch with over pressure on active hip flexion range of motion (rom) in those with active hip flexion rom limitations. there is limited evidence available in the literature examining the therapeutic effects of mwm at the hip, the long term effects of mwm, or whether one modality is more effective than another. this study seeks to address these gaps in the literature by directly comparing the results of these two manual therapy interventions on active hip flexion rom.

this study aims to compare the effects of a therapist-performed mobilization with movement (mwm) technique with those of a dynamic stretch with over pressure on active hip flexion range of motion (rom) in those with active hip flexion rom limitations.those individuals from the university of south carolina's department of physical therapy (uofsc dpt) community who are interested in becoming study participants will be identified by means of announcements made in the seminar in physical therapy course which is attended by all students, faculty, and staff of uofsc dpt each week. interested individuals will be provided with cathy arnot's email address in order to schedule an evaluation session to determine whether or not they meet the study's inclusion and exclusion criteria. in addition, sarah cooper will attend a staff meeting at vertex pt specialists to make an announcement and provide the attendees with cathy arnot's email for inquiries. participants will be assigned to either the mwm group or the dynamic stretch with over pressure group via blocked randomization for sex and age, with at least seventeen participants being placed into each group. the mwm group participants will receive a therapist-performed mwm technique and a prescription for a home exercise program (hep) consisting of a dynamic stretch with over pressure to be performed once a day over the course of the following week. the dynamic stretch with over pressure group participants will receive only the prescription for the hep consisting of the dynamic stretch with over pressure to be performed once a day over the following week. measurements will be assessed at four time points: immediately before the intervention, immediately after the intervention, 24 hours after the intervention, and one week after the intervention.

Eligibility criteria:
inclusion criteria: * the sole inclusion criterion will be a limitation in hip flexion to less than 101 degrees in both hips. exclusion criteria: * any traumatic injury to or surgical procedure performed upon the lower extremities within the last six months * any contraindication to dynamic stretching, weight-bearing rotation, or mwm of the hip joint * any dermatologic pathology in the area of the strap application * any pain provoked by active hip flexion.
optimizing the dose of flucytosine for the treatment of cryptococcal meningitis

Conditions: Cryptococcal Meningitis

Summary: cryptococcal meningitis (cm) is a fungal infection that causes a severe syndrome of meningitis that is 100% fatal without antifungal therapy. even with antifungal therapy, mortality rates remain high, especially in africa where the ongoing hiv/aids pandemic leads to higher prevalence of cryptococcosis. combination of amphotericin and flucytosine (5-fc) is the mainstay of therapy for the initial management of cm. indeed, it has even been shown that effective delivery of these therapies in africa can lower mortality rates by 90%. this is a prospective open-label trial to compare the efficacy and safety of lower doses of 5fc during induction therapy to historical controls with standard 5fc dosing. participants in the trial will receive 60mg/kg/day of 5-fc in 3 divided doses for 10 days. single-dose liposomal amphotericin (10mg/kg) is preferred, if available. amphotericin b 0.7-1.0 mg/kg/day may be used if needed. historical controls drawn from the ambition trial will be used as a comparison group, selected weighted by inclusion/exclusion criteria, baseline characteristics and therapies received. induction therapy for control group participants followed the 2018 who cryptococcal guidelines with 7 days of 5-fc 100mg/kg/day and 7 days of iv amphotericin deoxycholate followed by 1200mg fluconazole/day for 7 days. the intervention group received single- dose liposomal amphotericin plus 5-fc and fluconazole 1200 mg/day. all participants will receive fluconazole 1200mg/day during consolidation therapy from day 1 to 14 then 800mg/day from day 15 to 10 weeks, and 200mg/day after 10 weeks. all participants will receive lumbar punctures at diagnosis, day 3, day 5-7, day 10-14, and additionally as required for control of intracranial pressure and documentation of csf sterilization. controls from ambition will be matched for the same lp windows. therapeutic lps conducted during the first week have a \~70% relative survival benefit.


Eligibility criteria:
inclusion criteria: * csf cryptococcal antigen (crag) positive meningitis * ability and willingness to provide informed consent * willing to receive protocol-specified lumbar punctures exclusion criteria: * age \<18 years * inability to take enteral (oral or nasogastric) medicine * cannot or unlikely to attend regular clinic visits * receiving chemotherapy or corticosteroids * suspected paradoxical immune reconstitution inflammatory syndrome (iris) * pregnancy or breastfeeding * crcl \< 20 ml/minute * absolute neutrophil count \<500 x10 6 cells/l * thrombocytopenia \< 50,000 x 10 6 cells/l * patients with prior 5-flucytosine exposure \>3 days in the 12 months prior to enrollment * any condition for which participation would not be in the best interest of the participant or that could limit protocol specified assessments.
effect of prednisolone treatment on uterine natural killer cells

Conditions: Recurrent Miscarriage

Summary: this study aims to investigate the role of unk cells and the association with prednisolone.

glucocorticoids prednisolone is considered as a potential therapy in women with recurrent miscarriage. however, the evidence for treatment with prednisolone is still inconclusive and the relevant mechanism merits further investigations. the participants will be invited to take prednisolone oral 10 mg/day and attend our outpaitent clinic to be performed endometrial biopsy.

Eligibility criteria:
inclusion criteria: 1. women with a history of 3 or more consecutive miscarriages 2. women younger than 40 years old exclusion criteria: 1. allergy to prednisolone 2. women who have any uterine anomaly 3. antiphospholipid syndrome 4. hydrosalpinx 5. thrombophilia 6. abnormal thyroid function tests 7. women with diabetes,

Keywords: recurrent miscarriage prednisolone treatment
impact of formal home help on quality of life for caregivers of elderly patients with neurocognitive impairment

Conditions: Age-related Cognitive Decline

Summary: the purpose of this prospective monocenter observational study is to assess the impact of the first introduction of formal home help (personalized autonomy allowance for seniors) on the quality of life of home caregivers of elderly patients with neurocognitive impairment.

an aging population is leading to an increase in neurodegenerative disorders that are responsible for loss of autonomy. in order to keep patients with neurocognitive impairment at home, the availability of home caregivers is essential. the neurocognitive deterioration of elderly patients is a significant burden for home caregivers and can affect their quality of life. the implementation of formal home help (personalized autonomy allowance for seniors) can relieve home caregivers and improve their quality of life. conduct of research: elderly patients followed in the geriatric department of the mulhouse french hospital, and for whom a formal home help (personalized autonomy allowance for seniors) is initiated will be recruited. the evolution of home caregiver's quality of life, burden and vulnerability, will be assessed during three months.

Eligibility criteria:
inclusion criteria: * patient 60 years of age or older * diagnosis of neurocognitive disorders * mmse score less than or equal to 26 * gir score inferior or equal to 4 * introduction of formal home help (personalized autonomy allowance for seniors program) * patient living in haut-rhin department (france) * patient receiving regular informal help at home (at least once a week) * availability of the current home helper to participate in the sudy * non-opposition to participation in the study exclusion criteria: * introduction of formal home care not related to the personalized autonomy allowance program * patient under legal protection

Keywords: cognitive impairment caregiver quality of life caregiver burden caregiver vulnerability
study to characterize the long-term clinical experience of atacand in hypertensive children ages 1 to<11 years (hypertension in pediatrics)

Conditions: Hypertension

Summary: the hip study is designed to follow the clinical experience of young hypertensive children receiving candesartan cilexetil (atacand) who are between the ages of 1 and less than 11 years old. the study is open label with no concurrent control group. to be eligible for hip, children must have completed study 328 without discontinuation due to a study drug-related ae and in the investigator's opinion, have an on-going clinical indication for an orally administered suspension of candesartan cilexetil to control blood pressure. children will return to clinic every 3 months (more frequently at the investigator's discretion) for safety and efficacy evaluations. safety will be monitored by serum chemistries, urinalyses, echocardiograms and by physical examinations at specified clinic visits. blood pressure and heart rate will be measured at each clinic visit. study drug is administered orally once a day. investigators determine the efficacious dose ( 0.05 mg/kg; 0.2 mg/kg; 0.4 mg/kg) on a vist-by-vist basis depending on the child's bp response. it is anticipated that study dose will align closely with the effective anti-hypertensive dose determined in study 328. if the child's hypertension is not well-controlled, dose adjustments up to a maximum of 0.4mg/kg/day and/or the addition of other antihypertensive medications are permitted, with the exception of other angiotensin receptor blockers. the hip study offers eligible children up to two additional years of treatment with the liquid formulation of atacand.


Eligibility criteria:
inclusion criteria: * must have participated in protocol 328 (without discontinuation due to a study drug related ae). * must sign an informed consent prior to initiating any stus dy procedures. * have, in the opinion of the investigator, an on-going clinical indication for oral liquid formulation of candesartan cilexetil to control hypertension * weight ≥ 10 kg and ≤ 40 kg. exclusion criteria: * any situation, clinical condition (such as clinically significant declining renal function) or laboratory abnormality that, in the opinion of the investigator or sponsor, may interfere with the subject's participation in the study. * estimated glomerular filtration rate (gfr) \<30 ml/min/1.73m2 for non-transplant patients and \<40 ml/min/1.73m2 for transplant patients based on the schwartz formula (schwartz et al 1987) as determined at enrollment into study 328. * impaired liver function defined as either acute liver disease or chronic liver disease with persistently elevated liver enzyme values judged clinically significant by the investigator. * currently using any medications that, in the opinion of the investigator could negatively affect the subject when given together with candesartan cilexetil.

Keywords: pediatric renal disease high blood pressure
hbsag related response guided therapy

Conditions: Hepatitis B, Chronic

Summary: primary objective: compare pegasys rgt overall response rate (i.e., hbeag seroconversion rate) with pegasys mono historical response rate at week 72 (48 week treatment with 24 week follow up) secondary objective : * the changes of hbsag titer * the rate of combined hbeag seroconversion and hbv dna \< 300 copies/ml * the rate of serum hbv dna \< 300 copies/ml ⅳ. the rate of alt normalization * the rate of hbsag loss ⅵ. the rate of serum hbv dna \< 10,000 copies/ml

after 12w treatment of pegasys, depends on results of quantitative hbsag test, patients will be allocated to one of three groups. * hbsag \>20,000 : study termination * group a :1,500\<hbsag≤ 20,000 * group b : .hbsag ≤ 1500 at week 48, according to hbeag seroconversion, patients will be allocated to one of two sub-groups(a-1, a-2, b-1, b-2) patients are seen for evaluation at treatment weeks 4,8,12,24,36,48. post-treatment assessments will be performed at 4,12 and 24 week during off-treatment phase for the assessment of the primary and main secondary endpoints of the study.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. positive hbsag for more than 6 months, positive hbeag, detectable hbv dna(patients must have \> 100,000 copies/ml as measured by pcr) and anti-hbs negative 3. elevated serum alt \> 2uln but ≤ 10 × uln as determined by two abnormal values taken ≥ 14 days apart during the six months before the first dose of study drug with at least one of the determinations obtained ≤ 35 days prior to the first dose. exclusion criteria: 1. patients must not have received antiviral therapy for their chronic hepatitis b. patients who are expected to need systemic antiviral therapy other than that provided by the study at any time during their participation in the study are also excluded. exception: patients who have had less than 6 months treatment of na(nucleos(t)ide analog) and more than 1 year wash-out period for systemic antiviral therapy and negative results in the na resistance test at baseline are not excluded. 2. positive test at screening for hav igm ab, hcv-rna or hcv ab, hdv ab or hiv ab. 3. diagnosed hepatic cellular carcinoma 4. any evidence of decompensated liver disease (childs b-c)

Keywords: peginterferon alfa 2a entecavir response guided therapy chronic hepatitis b
detection of lung cancer by plasma lipids

Conditions: Early-Stage Lung Cancer

Summary: there are no reliable blood-based tests currently available for early-stage lung cancer diagnosis. we try to establish a highly accurate method for detecting early-stage lung cancer by combining machine learning with untargeted and targeted metabolomics .

all plasma lipids were first detected by untargeted metabolomics methods and 9 feature lipids of early-stage lung cancer were selected by support vector machine algorithm. then, a targeted metabolomics method was developed to detect the 9 lipids quantitatively based on multiple reaction monitoring mode. finally, a detection model was established based on the 9 lipids.

Eligibility criteria:
inclusion criteria: 1. pulmonary nodules or opacity 2. plan to receive surgery exclusion criteria: 1. history of other malignancies 2. received anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery

Keywords: early-stage lung cancer plasma metabolomics lipids machine learning
eplerenone in hemodialysis trial

Conditions: Hemodialysis; End Stage Renal Disease

Summary: forty percent of patients that require dialysis for kidney failure die within three years mostly due to heart disease. heart failure and high blood pressure are common problems in patients that require dialysis and are key causes of death due to heart disease. eplerenone is a drug that is very effective at improving heart failure and reducing blood pressure in patients that do not require dialysis. there is currently no evidence to tell physicians whether eplerenone would have similar benefits in patients that require dialysis. this evidence can only be reliably generated by performing a large scale study. before such a study is undertaken, the investigators must determine whether eplerenone will be well tolerated and safe in patients that require dialysis. the investigators will perform an initial small trial called the pilot trial in hemodialysis patients undergoing aldosterone antagonism with eplerenone (phase) to determine if eplerenone is a well tolerated, safe medication to use in a very large, global study that will show whether or not eplerenone reduces important outcomes for patients like death from heart causes.


Eligibility criteria:
inclusion criteria: * age ≥18 years * on hemodialysis \>90 days * prescribed target body weight within 1 kg of current for all dialysis sessions within 4 weeks prior to randomization * able to provide written informed consent to participate exclusion criteria: * occurrence of documented clinically important hypotension (systolic blood pressure \<90 that required treatment) within 4 weeks of randomization * change in blood pressure medications within 4 weeks prior to randomization * occurrence of pre-dialysis serum potassium \>6.0 mmol/l in 4 weeks prior to randomization * currently treated with and cannot withdraw spironolactone or eplerenone due to medical necessity * known allergy or sensitivity to eplerenone * pregnancy * scheduled living related donor renal transplant within the next 6 months
prognostic features for mortality in young adults with pneumonia

Conditions: Pneumonia

Summary: pneumonia is a major cause of mortality and morbidity. a large body of evidence concerning the mortality risk factors in elderly patients with pneumonia has been reported; however, less is known about causes of mortality in patients of sixty and less. we noted a relatively substantial rate of short term mortality in this group of patients that were admitted to our institution. therefore, we aimed to estimate the mortality rate and to identify risk factors for mortality among patients of sixty years old and less that were admitted with community acquired pneumonia.

community acquired pneumonia (cap) is a major cause of morbidity and mortality. while there is much data about risk factors for severe outcome in the general population, there is less focus on younger group of patients. therefore, we aimed to detect simple prognostic factors for severe morbidity and mortality in young patients with cap. patients 60 years old or younger, who were diagnosed with cap (defined as pneumonia identified 48 hours or less from hospitalization) between march 1, 2005 and december 31, 2008 were retrospectively analyzed for risk factors for severe morbidity or mortality. complicated hospitalization was defined as at least one of the following parameters: hospitalization longer than ten days, admission to intensive care unit and in- hospital mortality. otherwise, the hospitalization was defined uncomplicated

Eligibility criteria:
inclusion criteria: * patients with the diagnosis of community acquired pneumonia age between 18-60 exclusion criteria: age less than 18 and more than 60 transfer from another hospital hospitalization for any cause other than cap during the 30 days prior to admission hospital acquired pneumonia partial antibiotic treatment before admission.

Keywords: age mortality
apioc toric/spherical single vision contact lens

Conditions: Refractive Errors

Summary: the lentechs apioc-s and apioc-a contact lenses are made in an fda-approved contact lens material indicated for single-vision and astigmatism. the novel lens design has a lenticular portion which is thicker than the optical portion of the lens. when applied to the eye, it is oriented in a superior position. unlike contact lenses currently on the market, this innovative design improves lens stability by preventing lens rotation, and may improve tear flow behind the lens.


Eligibility criteria:
inclusion criteria: 1. the subject must provide written informed consent. 2. the subject must appear willing and able to adhere to the instructions set forth in this protocol. 3. at least 18 years of age and no more than 35 years of age. 4. ≤ 4.00 d of corneal astigmatism. 5. ≤ 4.00 d of refractive astigmatism. 6. refractive error range +20.00 ds to -20.00 ds 7. flat and steep keratometry readings within 40 to 50d. 8. clear, healthy corneas with no irregular astigmatism. 9. normal, healthy conjunctiva in both eyes. 10. free of active ocular disease. refractive error is permitted. 11. be a current or former (within the last 12 months) contact lens wearer. 12. best-corrected near and distance visual acuity better than or equal to 20/25. exclusion criteria: 1. irregular corneal astigmatism. 2. presbyopia 3. corneal scarring unless off line-of-site and well healed. 4. pinguecula, pterygium, or other conjunctival thickness abnormalities that would interfere with soft contact lens wear. 5. recent use of any ocular pharmaceutical treatments, including daily artificial tears, in the two weeks prior to the examination. use of artificial tears less than 3 drops per week is permitted. 6. systemic disease that would interfere with contact lens wear. 7. currently pregnant or lactating (by self-report). 8. history of strabismus or eye movement disorder. 9. active allergies that may inhibit contact lens wear. 10. upper eyelid margin at or above the superior limbus. 11. history of ocular or lid surgery.

Keywords: contact lens soft contact lens
validation of proteomic analyses for allergic asthma and rhinitis

Conditions: Rhinitis, Allergic; Asthma, Allergic

Summary: the purpose of this study is to verify and validate the intrinsic diagnostic value in terms of sensitivity and specificity of proteomic profiles determined during a pre-study for discriminating between allergy related asthma and allergy related rhinitis.


Eligibility criteria:
inclusion criteria: * signed consent * never-smokers or non-smoking for at least 2 years + \< 5 packs per year * capable of understanding the study * patient is affiliated with a social security system * positive skin tests (at least one for montpellier region pneumoallergens) * treated with nasal or inhaled corticoids, leucotriene receptor antagonists, anti-ige, theophylline, anti-histamines, sodium cromoglycate, beta-blockers, benzodiazépine, oral corticoids: all these treatments must be interrupted for at least 72 hours exclusion criteria: * co-morbidities: none; no co-morbidities are accepted * dental infections (any) during the 3 months preceding the study * suspected alcoholism or drug abuse * chronic viral infection (hepatitis, hiv) * patient under guardianship